ADIM
CDLX icon

Alpha DNA Investment Management’s Cardlytics CDLX Stock Holding History

Alpha DNA Investment Management’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3
Closed -$2K – 185
2021
Q1 		$2K Buy
+3
New +$3.96K ﹤0.01% 553

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACM
Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return

Alpha DNA Investment Management's CDLX Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of Cardlytics (CDLX) in Q2 2021, closing a stake of 3 shares — an estimated $2K sold.

Alpha DNA Investment Management first reported a position in CDLX in Q1 2021 and held it in 1 quarter. The position peaked at $2K in Q1 2021. 189 funds tracked by Wall St. Rank hold CDLX as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining Cardlytics position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 3 Cardlytics shares in Q2 2021, an estimated $2K.
  • Alpha DNA Investment Management first reported a position in Cardlytics in Q1 2021 and held it in 1 quarter.
  • Alpha DNA Investment Management's Cardlytics position peaked at $2K in Q1 2021.
  • 189 funds tracked by Wall St. Rank held Cardlytics as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.